Side-by-side · Research reference
ARA 290vsSNAP-8
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BHuman-MechanisticHUMAN-REVIEWED8/46 cited
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily
01Mechanism of Action
Parameter
ARA 290
SNAP-8
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
SNARE complex (SNAP-25 competitive binding site)
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
N/A — topical cosmetic, no systemic endocrine axis
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
SNAP-8
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
RCT, in vitro skin penetration studies
Timing
Any time of day
No circadian dependence reported.
—
Typical concentration
—
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
Treatment duration
—
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
Formulation type
—
Oil-in-water emulsion, serum, cream
Application site
—
Facial skin — glabellar lines, crow's feet, forehead
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
SNAP-8
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
SNAP-8
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Cytotoxicity
—
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
Skin irritation
—
Minimal; well-tolerated in clinical use
Peptide oxidation
—
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
Hypersensitivity
—
Rare; no widespread allergic reactions reported
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
SNAP-8
- ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
SNAP-8
- ·Active skin infections or open wounds at application site
- ·Neuromuscular disorders (theoretical concern, no documented cases)
05Administration Protocol
Parameter
ARA 290
SNAP-8
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
6. Duration
—
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
SNAP-8
— no documented stacks